A 2019 TOP DOC
Dr. Maria Jacobs leads the Radiation Oncology team at Mercy Medical Center bringing passion, enthusiasm and a heart for caring to her patients.
Mercy’s team of breast surgeons and breast cancer specialists in Baltimore help women determine the best breast cancer treatment options available to them.
The Breast Reconstruction and Restoration Center at Mercy is led by Dr. Bernard (Bernie) Chang, and Dr. Brendan Collins -recognized specialists in breast reconstruction and restoration.
Mercy offers emergency care on the Downtown Baltimore campus 24 hours a day, 7 days a week (410-332-9477) with access to a trained emergency medicine team, diagnostic services and consultations with specialists.
In case of an Emergency, Dial 911 and follow the instructions of the EMS (Emergency Medical Services) team.
Mercy Medical Center's downtown campus includes our Main Hospital - The Mary Catherine Bunting Center, McAuley Plaza and The Weinberg Center.
General visiting hours at Mercy are 11:00 am to 8:30 pm. Hours vary by floor, please check with the nursing staff or call 410-332-9555.
Currently Displaying: Active Clinical Trials
This is a Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (Clinicaltrials.gov ID#: NCT03726879).
This is a research study comparing Atezolizumab (Anti-PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple‑negative breast cancer. (Clinicaltrials.gov ID#: NCT03498716)
This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). This study will help to show whether weight loss programs should be a part of breast cancer treatment. (Clinicaltrials.gov ID#: NCT02750826)
This is a phase II randomized trial evaluate the efficacy and Safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2- negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment. (Clinicaltrials.gov ID#: NCT03056755)
This is a double-blind, placebo-controlled, randomized phase III study of ipatasertib in combination with paclitaxel as a treatment for patients with PIK3CA/AKT1/PTEN-altered, locally advanced or metastatic, triple-negative breast cancer or hormone receptor–positive, HER2-negative breast cancer (Clinicaltrials.gov ID#: NCT03337724).
This trial compares DS-8201a, an anti-HER2-antibody drug conjugate, versus standard of care for HER2-positive, unresectable and/or metastatic breast cancer subjects pretreated with prior standard of care HER2 therapies, including T-DM1. (ClinicalTrials.gov ID#: NCT03523585)
This is a phase III trial to determine how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with triple-negative breast cancer who have residual disease following neoadjuvant chemotherapy and surgery. (Clinicaltrials.gov ID#: NCT02445391)
This trial compares the efficacy and safety of elacestrant to the standard of care fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on at least one endocrine therapy. (ClinicalTrials.gov ID#: NCT03778931)
This study is designed for patients desiring nipple reconstruction following surgery for breast cancer and breast reconstruction. Eligible patients will receive a surgical procedure to reconstruct one or both nipples utilizing the COOK® Biodesign® Plastic Surgery Matrix. The study is designed to evaluate the benefit of this device in achieving effective and aesthetic nipple reconstruction. Patients will be evaluated at the time of the procedure and at 1 week, 4 weeks, 3 months, 6 months, and 12 months after surgery to examine the projection of their reconstructed nipple(s) and patient satisfaction (Cook Medical Study 09-009; Clinicaltrials.gov ID#: NCT01216319).
The purpose of this registry is to create a large-scale, population-based database. This database will match health information to genome information to look at the Agendia Breast Cancer suite and new gene associations. The Agendia Breast Cancer Suite includes MammaPrint® and BluePrint™, which are tests that help your doctor analyze and profile your breast cancer tumor. DiscoverPrint is for research purposes only. (Clinicaltrials.gov ID#: NCT03053193)
This study is researching the link between insulin resistance and breast cancer prognosis in African American and Caucasian women.
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (Clinicaltrials.gov ID#: NCT03701334).
This is a non-interventional trial for patients receiving palbociclib for their hormone positive advanced breast cancer. (Clinicaltrials.gov ID#: NCT03280303)
This is a phase III randomized trial evaluate the efficacy and safety of pembrolizumab for women with triple-negative breast cancer who have residual invasive cancer or positive lymph nodes after neoadjuvant chemotherapy. (Clinicaltrials.gov ID#: NCT02954874)
This is an observational study for women who are receiving Intraoperative Radiation Therapy (IORT) following breast-conserving surgery. (ClinicalTrials.gov ID#: NCT01570998)
The Hoffberger Breast Center at Mercy Medical Center in Baltimore, Maryland, features some of the Mid-Atlantic’s top rated breast cancer doctors, surgeons and specialists in a comfortable, caring atmosphere within The Weinberg Center for Women’s Health & Medicine. The Breast Center provides the Baltimore region with expertise in patient treatment for diseases and conditions including breast cancer, breast lumps, breast calcifications, nipple discharge and cysts. Our Doctors offer advanced treatment options and were the first in Maryland to treat patients using (IORT) intraoperative radiation therapy.
Dr. Bernie Chang is Director of Plastic & Reconstructive Surgery at Mercy and also leads The Breast Reconstruction and Restoration Center. He pioneered treatment options like DIEP flap breast reconstruction.